Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two antifungal agents, an echinocandin (such as caspofungin, micafungin, or anidulafungin) and fluconazole. Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-(1,3)-D-glucan in the fungal cell wall by noncompetitive inhibition of the enzyme 1,3-β-D-glucan synthase. This disrupts cell wall integrity and leads to fungal cell death or growth inhibition[6][8][10]. Fluconazole is a triazole antifungal that inhibits ergosterol synthesis in fungal cell membranes by targeting lanosterol 14α-demethylase[4]. The combination has been studied for potential additive or synergistic effects against Candida species and other fungi; however, clinical results have been mixed and often show no clear superiority over monotherapy with either agent[3][5]. Both drugs are used primarily for invasive candidiasis and other serious systemic fungal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinocandin + fluconazole.